文献速递乳腺癌头颈与中枢神经肿瘤支持与姑息治疗

接受单克隆抗体治疗患者自然杀伤细胞CD137上调的特征分析

Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy.
PubMed 文献 · Ann Oncol · 2017-01-01

研究纳入199例接受单克隆抗体治疗的乳腺癌、头颈癌和非霍奇金淋巴瘤患者,用流式细胞术评估治疗前后CD137表达,并采用CART、lasso回归和随机森林分析预测因素。结果显示不同癌种CD137表达差异显著,FcR多态性、基线CD137表达和年龄为CD137上调的显著预测因素,作者认为开发列线图可行。

要点

  • 不同癌种CD137表达差异显著:乳腺癌均值6.6(SD 6.5),头颈癌11.0(SD 7.0),非霍奇金淋巴瘤7.5(SD 7.1),P<0.0001。
  • 乳腺癌和非霍奇金淋巴瘤中,FcR多态性和基线CD137表达是CD137表达增加的显著预测因素。
  • 头颈癌中,FcR多态性和年龄是CD137表达增加的显著预测因素。

核心结论

  • 初步结果提示FcR多态性、治疗前CD137表达和年龄是患者CD137上调的显著预测因素。
  • 本研究表明开发用于治疗反应的列线图是可行的。
  • 在独立队列中验证模型将是开发列线图的下一步,该列线图可能用于个体化治疗。

研究设计与样本

  • 收集199例接受单克隆抗体治疗作为临床试验一部分的患者资料,包括乳腺癌62例、头颈癌46例和非霍奇金淋巴瘤91例。
  • 通过流式细胞术评估单克隆抗体治疗前后CD137表达的差异。
  • 应用分类与回归树(CART)、多变量lasso回归工具和随机森林评估通过CD137表达增加对单克隆抗体治疗应答的患者。

主要发现

  • CD137表达在各癌种间显著不同:乳腺癌均值6.6(SD 6.5),头颈癌11.0(SD 7.0),非霍奇金淋巴瘤7.5(SD 7.1),P<0.0001。
  • 乳腺癌和非霍奇金淋巴瘤中,FcR多态性和基线CD137表达是CD137表达增加的显著预测因素。
  • 头颈癌中,FcR多态性和年龄是CD137表达增加的显著预测因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者称结果为初步结果。
  • 作者指出需在独立队列中验证模型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the era of personalized cancer medicine, identifying techniques for effectively matching patients to efficacious treatments is a critical step in the treatment process. The advent of anti-cancer immunotherapies necessitates novel approaches to biomarker identification beyond traditional genomic profiling. One promising approach is incorporation of nomograms into treatment decisions. Nomograms are prediction tools, based on statistical modeling, designed to predict treatment outcomes. As a first step toward developing a nomogram, we conducted analyses to predict CD137 expression of natural killer cells after monoclonal antibody (mAb) treatment. PATIENTS AND METHODS: Patient, tumor and immune characteristics were collected from 199 patients with breast cancer (N = 62), head/neck cancers (N = 46) and non-Hodgkin's lymphoma (NHL) (N = 91), who were receiving mAb therapy as part of clinical trials. The difference in CD137 expression before and after mAb therapy was assessed by flow cytometry. To evaluate those who respond to mAb therapy via increased CD137 expression, we applied classification and regression trees (CART), multivariable lasso regression tools and Random Forest. RESULTS: The CD137 expression was significantly different for each cancer type [mean (SD): Breast: 6.6 (6.5); Head/Neck: 11.0 (7.0); NHL: 7.5 (7.1), P < 0.0001]. For breast cancer and NHL, FcR polymorphism and baseline CD137 expression were significant predictors of increased CD137 expression; for head/neck cancer, FcR polymorphism and age were significant predictors of increased expression. CONCLUSIONS: Our preliminary results suggest that FcR polymorphism, pre-treatment CD137 expression and age are significant predictors of CD137 upregulation in patients. This study demonstrates that the development of a nomogram for therapy response is feasible. Further work validating our models in an independent cohort will provide the next steps in developing a nomogram that may be used to individualize this therapeutic approach for patients (NCT01114256).

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Makkouk A, Sundaram V, Chester C, et al. Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy. Ann Oncol. 2017. PMID: 27831501. doi:10.1093/annonc/mdw570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。